platinum has been researched along with Urinary Bladder Neoplasms in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.22) | 18.7374 |
| 1990's | 4 (4.12) | 18.2507 |
| 2000's | 5 (5.15) | 29.6817 |
| 2010's | 16 (16.49) | 24.3611 |
| 2020's | 65 (67.01) | 2.80 |
| Authors | Studies |
|---|---|
| Adib, E; Alva, AS; Curran, C; Diamantopoulos, LN; Grivas, P; Jain, RK; Kazakova, V; Marandino, L; Merchan, JR; Necchi, A; Plastini, TM; Sonpavde, G; Su, C; Tandon, A | 1 |
| Abe, T; Araki, H; Fujiwara, M; Hikami, K; Inokuchi, J; Ito, K; Kato, M; Kitamura, H; Kobayashi, T; Kojima, T; Kurahashi, R; Matsui, Y; Matsumoto, K; Nakamura, K; Nishiyama, H; Ogawa, K; Ogawa, O; Ozaki, Y; Sassa, N; Shimizu, K; Takahashi, A; Tashiro, Y; Tatarano, S; Tomida, R; Tsuchihashi, K; Uchida, J; Uegaki, M; Yamada, T; Yokomizo, A | 1 |
| Andresen, C; Bajorin, D; Burris, H; Daneshmand, S; De Giorgi, U; Galsky, M; Grivas, P; Gupta, S; Hoffman-Censits, J; Li, A; Lyou, Y; Moran, S; Pal, SK; Petrylak, D; Quinn, DI; Rearden, J; Rosenberg, JE; Vaishampayan, U; Xu, C | 1 |
| Babasaki, T; Harada, K; Hayashi, T; Maruyama, R; Murai, J; Pham, QT; Pommier, Y; Sakamoto, N; Sekino, Y; Sentani, K; Takashima, T; Takeda, M; Taniyama, D; Ukai, S; Yasui, W | 1 |
| Hirayama, Y; Kato, M; Kuratsukuri, K; Otoshi, T; Takeyama, Y; Uchida, J; Yamamoto, S; Yamasaki, T; Yukimatsu, N | 1 |
| Bamias, A; Bell-McGuinn, KM; Castellano, D; de Wit, R; Drakaki, A; Fléchon, A; Gao, L; Lee, JL; Long, A; Matsubara, N; Necchi, A; Petrylak, DP; Powles, T; Sternberg, CN; van der Heijden, MS; Walgren, RA; Yu, EY; Zimmermann, AH | 1 |
| An, X; Hu, A; Huang, R; Li, H; Li, L; Ni, M; Shi, Y; Xue, C; Yang, W | 1 |
| Banna, GL; Calabro, F; Emeribe, U; Fléchon, A; Hellmis, E; Hotte, SJ; Lee, JL; Lima, AR; Loriot, Y; Marabelle, A; Miranda, PAP; Oh, SM; Pouessel, D; Powles, T; Roubaud, G; Shin, SJ; Sonpavde, GP; Sternberg, CN; Vera-Badillo, FE; Zagonel, V | 1 |
| Agarwal, N; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberón, MC | 1 |
| Balar, A; Campbell, M; Galsky, MD; Heath, EI; Hepp, Z; Mazerolle, F; McGregor, B; McKay, C; O'Donnell, PH; Petrylak, D; Quinn, DI; Regnault, A; Rosenberg, J; Steinberg, J; Yu, EY | 1 |
| Attwood, K; Cao, Q; Chatta, G; Goodrich, DW; Guru, KA; Katsuta, E; Li, QJ; Smith, GJ; Takabe, K; Wang, J; Wang, L; Wei, L; Wu, Y; Xu, B; Xu, D | 1 |
| Aversa, C; Buijtenhuijs, B; Choudhury, A; Conroy, R; Croxford, W; Das, A; Doss, G; Elumalai, T; Enting, D; Hoskin, P; Kitetere, E; Law, A; Mistry, H; Sanderson, B; Tolan, S; Vasudev, NS | 1 |
| Bajorin, DF; Braverman, J; Broughton, E; Galsky, MD; Gschwend, JE; Guo, S; Hamilton, M; Maira-Arce, M; Nasroulah, F; Shi, L; Witjes, JA; Ye, X | 1 |
| Hadaschik, B; Herold, T; Mairinger, FD; Reis, H; Szarvas, T; Wessolly, M | 1 |
| Hur, JY; Hwang, I; Jung, JY; Keam, B; Kim, C; Kim, HJ; Kim, IH; Lee, HJ; Lee, JL; Lee, MY; Maeng, CH; Park, I; Park, JH; Park, K; Park, SH | 1 |
| Bian, XJ; Cai, J; Chen, C; Han, W; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xing, N; Ye, DW; Zhang, X; Zou, Q | 1 |
| Boellaard, TN; de Feijter, JM; Einerhand, SMH; Hendricksen, K; Schaake, EE; van de Kamp, MW; van der Heijden, MS; van Dijk, N; van Dorp, J; van Montfoort, ML; van Rhijn, BWG | 1 |
| Bamias, A; Caserta, C; Chang, J; Cislo, P; Climent Duran, MA; di Pietro, A; Fong, PC; Grivas, P; Kopyltsov, E; Park, SH; Parnis, FX; Powles, T; Su, PJ; Tournigand, C; Wang, J; Yamamoto, Y | 1 |
| Alati, A; Bibault, JE; Charles-Nelson, A; Durdux, C; Fabiano, E; Geiss, R; Giraud, P; Housset, M; Kreps, S; Mareau, A; Méjean, A | 1 |
| Bajorin, DF; Castellano, D; Dao, TV; Dry, H; Howells, K; Kozlov, V; Lanasa, MC; Li, JR; Mukherjee, SD; Park, SH; Rosenberg, JE; Stewart, R | 1 |
| Chen, X; Lin, T; Liu, S | 1 |
| Anari, F; Geynisman, DM; Ghatalia, P; Handorf, E; Miron, B; Plimack, ER; Zarrabi, K; Zibelman, MR | 1 |
| Einerhand, SMH; van der Heijden, MS; van Dijk, N; van Rhijn, BWG | 1 |
| Takahashi, T | 1 |
| Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A | 1 |
| Inokuchi, J; Ito, K; Kawahara, T; Kita, Y; Kitamura, H; Kobayashi, T; Kurahashi, R; Maruyama, S; Matsumoto, K; Morita, S; Mukai, S; Otsuka, H; Ozaki, Y; Sano, T; Segawa, T; Takahashi, A; Tomida, R; Tsutsumi, M; Uegaki, M | 1 |
| Charchanti, A; Chatzopoulos, K; Christodoulou, C; Fostira, F; Foukas, P; Fountzilas, G; Goussia, A; Koliou, GA; Kotoula, V; Koumarianou, A; Nifora, M; Papadopoulou, K; Pectasides, D; Psyrri, A; Samantas, E; Tsiatas, M; Tsimiliotis, D; Visvikis, A | 1 |
| Adachi, T; Azuma, H; Egawa, S; Fukuokaya, W; Fukushima, T; Hashimoto, T; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Miki, J; Mori, K; Nakamori, K; Nakamura, K; Nishimura, K; Nishio, K; Ohno, Y; Shiroki, R; Takahara, K; Tsuduki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yanagisawa, T; Yano, Y; Yoshizawa, A | 1 |
| Abe, H; Fukuokaya, W; Hashimoto, M; Imai, Y; Ito, K; Iwatani, K; Kimura, S; Kimura, T; Koike, Y; Miki, J; Onuma, H; Oyama, Y; Tsuzuki, S; Urabe, F; Yamamoto, S; Yanagisawa, T | 1 |
| Aieta, M; Atzori, F; Bimbatti, D; Carella, C; De Giorgi, U; Di Maio, M; Di Napoli, M; Ermacora, P; Gamba, T; Giannatempo, P; Hamzaj, A; Ignazzi, G; Lolli, C; Masini, C; Pierantoni, F; Pignata, S; Procopio, G; Santini, D; Scandurra, G; Stellato, M; Tambaro, R; Veccia, A; Vignani, F; Zonno, A | 1 |
| Plimack, ER; Zibelman, MR | 1 |
| Bonnet, I; Boutrois, J; Brachet, PE; Castera, M; Clarisse, B; Coquan, E; Goardon, N; Grellard, JM; Joly, F; Lequesne, J; Meriaux, E; Nevière, Z; Thiery-Vuillemin, A; Travers, R | 1 |
| Albisinni, S; Mjaess, G; Pochet, C; Quackels, T; Roumeguère, T; Sarkis, J; Vannier, E | 1 |
| Goto, Y | 1 |
| Ito, K; Kita, Y; Kobayashi, T | 1 |
| Chen, Y; Han, R; Hao, Y; He, X; Liu, Q; Liu, T; Qian, Z; Yang, C; Yang, Y | 1 |
| Abu El-Ela, RY; El-Bassiouny, NA; Hamza, MS; Kassem, AB; Salahuddin, A; Selim, MS | 1 |
| Baretton, G; Bolenz, C; Foller, S; Grimm, MO; Grün, CB; Leucht, K; Loidl, W; Meran, J; Niegisch, G; Pichler, M; Roghmann, F; Schmitz, M; Schmitz-Dräger, B; Schostak, M; Schumacher, U; Zengerling, F | 1 |
| Chan, TTW; Desai, C; di Pietro, A; Eto, M; Gao, S; Gurney, H; Lee, JL; Park, SH; Sandner, R; Su, PJ; Tsuchiya, N; Wang, J | 1 |
| Ajmera, M; Bellmunt, J; Candrilli, SD; Cappelleri, JC; Chang, J; Costa, N; Esterberg, E; Hitchens, A; Kearney, M; Pavilack-Kirker, M | 1 |
| Albers, P; Bannowsky, A; Becht, E; Fischer, C; Heinzelbecker, J; Hofmann, R; Kamradt, J; Kuehn, M; Langbein, S; Lehmann, J; Müller, M; Retz, M; Spieler, N; Steiner, G; Stoeckle, M; Volkmer, B; von Rundstedt, F; Wagenpfeil, G; Weber, HM; Wellek, S | 1 |
| Foller, S; Grimm, MO; Leeder, M; Leucht, K | 1 |
| Chen, R; Li, H; Wang, J; Wen, R; Zhou, J; Zhu, J | 1 |
| Agarwal, N; Bakaloudi, DR; Bamias, A; Barrera, RM; Brown, JR; Buznego, LA; Carballeira, CC; Castellano, D; Diamantopoulos, LN; Drakaki, A; Duran, I; Frobe, A; Grivas, P; Gupta, S; Jindal, T; Johnson, J; Khaki, AR; Korolewicz, J; Koshkin, VS; Lin, GI; Makrakis, D; Marmorejo, D; McKay, RR; Miletić, M; Murgić, J; Pinato, DJ; Rey-Cárdenas, M; Rodriguez-Vida, A; Ruplin, AT; Stewart, T; Talukder, R; Tripathi, N; Yu, EY; Zakharia, Y; Zakopoulou, R | 1 |
| Bhanegaonkar, A; Bilen, MA; Kim, R; Liu, FX; Peng, J; Robinson, SB; Schroeder, A | 1 |
| Augusto, I; Cruz, A; Mansinho, A; Marconi, L; Pinto, C | 1 |
| Benedict, A; Chang, J; Chou, P; Goh, C; Kapetanakis, V; Kearney, M; Kuo, K; Lin, AY; Liu, K; Palencia, R; Su, PJ; Wu, E; Xiao, Y | 1 |
| Bamias, A; Castellano, D; Drakaki, A; DuPree, K; Fléchon, A; Friedlander, T; Gomez-Roca, C; Joly Lobbedez, F; Lee, JL; Martin-Liberal, J; Michielin, F; Morales-Barrera, R; Moreno-Candilejo, I; Park, C; Powles, T; Rishipathak, D; Shemesh, CS; Shin, SJ; Steinberg, EE; Tosi, D; Williams, P; Young, F; Yuen, K | 1 |
| Burns, KD; Carroll Bullock, A; Conway, D; Devgan, G; Kehoe, K; Lapuente, M; Wood, LS | 1 |
| Akiyama, Y; Ambe, Y; Enomoto, Y; Fujimura, T; Fukuhara, H; Furuya, Y; Kakutani, S; Kamei, J; Kaneko, T; Kawai, T; Kishitani, K; Kume, H; Miyakawa, J; Nakagawa, T; Nakamura, Y; Nishimatsu, H; Noda, M; Obinata, D; Sato, Y; Sugimoto, K; Taguchi, S; Takahashi, S; Uemura, Y; Yamada, D; Yamada, Y; Yamaguchi, K | 1 |
| Alt, M; Goluboff, ET; Kazeem, G; Lin, Y; Sridhar, SS; Stecca, C | 1 |
| Chen, L; Deng, J; Fu, B; Li, S; Liu, T; Liu, X; Nie, J; Xiong, S; Xu, S; Zeng, J | 1 |
| Hashimoto, T | 1 |
| Cathomas, R; Fear, S; Haefeli, J; Llado, A; Mach, N; Pless, M; Riklin, C; Schardt, J; Stenner, F | 1 |
| Aguiar, MC; Botelho, MF; Brites, G; Brito, AF; Casalta-Lopes, J; Gonçalves, AC; Laranjo, M; Nascimento, BFO; Pereira, NAM; Pineiro, M; Pinho E Melo, TMVD; Sarmento-Ribeiro, AB | 1 |
| Al-Ahmadie, H; Bajorin, DF; Balar, AV; Bochner, BH; Dalbagni, G; Funt, SA; Iyer, G; Lee, CH; Li, HA; Milowsky, MI; Mota, JM; Ostrovnaya, I; Pietzak, E; Rosenberg, JE; Solit, DB; Teo, MY; Whiting, KA | 1 |
| Alfred Witjes, J | 1 |
| Black, PC; Contreras-Sanz, A; Roumiguie, M | 1 |
| Fujita, N; Hagiwara, K; Hashimoto, Y; Hatakeyama, S; Konishi, S; Noro, D; Ohyama, C; Okamoto, T; Okita, K; Suzuki, Y; Tanaka, T; Tokui, N; Yamamoto, H; Yoneyama, T | 1 |
| Agarwal, A; Barata, P; Bilen, MA; Curran, C; Drakaki, A; Garcia, J; Grivas, P; Gupta, R; Hussain, SA; Kanesvaran, R; Lee, JL; Lorenzo, GD; Ornstein, M; Pond, GR; Sonpavde, G; Verolino, P | 1 |
| Alessi, A; Briganti, A; Calareso, G; Colecchia, M; Madison, R; Marandino, L; Martini, A; Montorsi, F; Necchi, A; Raggi, D; Ross, JS | 1 |
| Habuchi, T; Hashimoto, Y; Hatakeyama, S; Kobayashi, M; Muto, Y; Narita, S; Narita, T; Noro, D; Numakura, K; Ohyama, C; Saito, M; Tanaka, T; Tokui, N; Yoneyama, T | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Bellmunt, J; Crabb, SJ; De Giorgi, U; Do, OA; Dorff, TB; Ferris, LA; Galsky, MD; Harshman, LC; Holt, SK; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Ramos, JD; Srinivas, S; Sternberg, CN; Vaishampayan, UN; Wong, RL; Yu, EY | 1 |
| Hwang, B; Kim, WJ; Lee, JW; Moon, B; Moon, SK; Noh, DH; Park, SL; Park, SS; Shin, SS | 1 |
| Albertson, DJ; Butterfield, A; Cairns, BR; Dalley, B; Gupta, S; Lowrance, WT; O'Shea, JM; Pappas, LM; Parnell, TJ; Schiffman, JD; Sharma, S; Weston, A | 1 |
| Chen, Y; Deng, Y; Huang, S; Li, R; Li, S; Peng, Q; Qin, X; Tang, W; Wang, J; Wu, J; Xie, L; Zhao, J | 1 |
| Goebell, P; Hegele, A; Matz, U; Neuhaus, T | 1 |
| Abida, W; Bajorin, DF; Rosenberg, JE | 1 |
| Apollo, A; Bajorin, DF; Bambury, RM; Benjamin, DJ; Chaim, JL; Garcia-Grossman, IR; Iyer, G; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Sullivan, J; Voss, MH; Xiao, H; Zabor, EC | 1 |
| Ito, Y; Kikuchi, E; Kosaka, T; Miyajima, A; Mizuno, R; Oya, M; Shinojima, T; Suzuki, E; Tanaka, N; Umezawa, K | 1 |
| Arai, G; Eto, M; Itoh, K; Kakuma, T; Komatsu, N; Matsueda, S; Matsumoto, K; Moriya, F; Naito, S; Nasu, Y; Noguchi, M; Ohyama, C; Sasada, T; Suekane, S; Tanaka, M; Uemura, H; Yamada, A | 1 |
| Guancial, E; Iczkowski, KA; Kilari, D; Kim, ES; Messing, EM; Pandya, C; Robin, AJ | 1 |
| Abu-Farsakh, SH; Baran, A; Guancial, EA; Kilari, D; Kim, ES; Messing, EM; Xiao, GQ | 1 |
| Cetraz, M; Golubev, V; Hartwig, A; Köberle, B; Schoch, S; Sen, V; Streule, K | 1 |
| Basso, U; Basterretxea, L; Bielle, J; Del Muro, XG; Guillot, A; Houédé, N; Lainez, N; Locker, G; Lucas, C; Lusuardi, L; Morelli, F; Parra, HS; Spaeth, D; Tambaro, R; Theodore, C; Tonini, G | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Sidaway, P | 1 |
| Eguchi, S; Hara, T; Hinoda, Y; Kawai, Y; Matsumoto, H; Matsuyama, H; Nagao, K; Naito, K; Sakano, S; Sasaki, M; Shinohara, A; Wada, T | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Bukovec, N; Cemazar, M; Grabner, S; Kosmrlj, J | 1 |
| Bernhardt, G; Brunner, H; Knuechel, R; Lottner, C | 2 |
| Buice, RG; Soloway, MS | 1 |
| Wasan, H; Waxman, J | 1 |
| Hoshi, S; Mao, H; Nose, M; Orikasa, S; Suzuki, K; Takahashi, T | 1 |
| Matsuda, T; Mikami, O; Oguchi, N; Okada, H; Uchida, J | 1 |
| Koga, H; Kotoh, S; Naito, S; Nakashima, M; Tanaka, M; Yokomizo, A | 1 |
| Albiol, S; Bellmunt, J | 1 |
| Culp, DA; Loening, SA; Narayana, AS | 1 |
| Matsuyama, H; Sakatoku, J; Shimabukuro, T; Wada, T; Yamamoto, N; Yoshihiro, S | 1 |
| Terashima, Y | 1 |
| Hoshi, S; Imai, Y; Ono, K; Orikasa, S; Tochigi, T; Yoshikawa, K | 1 |
| Bedford, P; Fichtinger-Schepman, AM; Hill, BT; Masters, JR; Shellard, SA; Walker, MC | 1 |
| Aoki, K; Baba, T; Hasuda, K; Kuroiwa, T; Taniguchi, S | 1 |
| deKernion, JB; Persky, L; Rose, D; Soloway, MS | 1 |
14 review(s) available for platinum and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
Topics: Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Platinum; Programmed Cell Death 1 Receptor; Urinary Bladder Neoplasms | 2022 |
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Immunologic Factors; Immunotherapy; Male; Platinum; Urinary Bladder Neoplasms | 2022 |
Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
Topics: Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Platinum; Tumor Microenvironment; Urinary Bladder Neoplasms | 2022 |
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
Topics: Carcinoma, Transitional Cell; Cisplatin; Humans; Platinum; Urinary Bladder Neoplasms | 2023 |
Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Humans; Immunotherapy; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Platinum; Urinary Bladder Neoplasms | 2022 |
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
Topics: Antineoplastic Agents; Cisplatin; Dicarboxylic Acid Transporters; Humans; Organic Cation Transport Proteins; Platinum; Urinary Bladder Neoplasms | 2023 |
[Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Topics: Carcinoma, Transitional Cell; Humans; Immunoconjugates; Immunotherapy; Platinum; Urinary Bladder Neoplasms | 2023 |
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Urinary Bladder Neoplasms | 2023 |
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms | 2023 |
ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Topics: Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Humans; Platinum; Urinary Bladder Neoplasms | 2014 |
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Metastasis; Platinum; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Platinum-based chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Neoplasm Staging; Platinum; Treatment Outcome; Urinary Bladder Neoplasms | 1994 |
New chemotherapy combinations for advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2001 |
19 trial(s) available for platinum and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Platinum; Ramucirumab; Urinary Bladder Neoplasms | 2022 |
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Urinary Bladder Neoplasms; Urinary Tract; Urologic Neoplasms | 2022 |
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
Topics: Adult; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Fatigue; Female; Humans; Immune Checkpoint Inhibitors; Male; Pain; Platinum; Programmed Cell Death 1 Receptor; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Topics: B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Muscles; Nivolumab; Platinum; Programmed Cell Death 1 Receptor; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Indoles; Male; Platinum; Pyrroles; Urinary Bladder Neoplasms | 2022 |
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Neoadjuvant Therapy; Nivolumab; Platinum; Urinary Bladder Neoplasms | 2022 |
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Patient Reported Outcome Measures; Platinum; Quality of Life; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Urinary Bladder Neoplasms | 2023 |
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms | 2023 |
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Humans; Maintenance Chemotherapy; Platinum; Progression-Free Survival; Urinary Bladder Neoplasms | 2023 |
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Immunotherapy; Ipilimumab; Male; Middle Aged; Nivolumab; Platinum; Urinary Bladder Neoplasms | 2023 |
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Platinum; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Follow-Up Studies; Gemcitabine; Humans; Platinum; Quality of Life; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Topics: Carcinoma, Transitional Cell; Humans; Immunologic Factors; Platinum; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Pyridines; Urinary Bladder Neoplasms | 2021 |
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Platinum; Retreatment; Treatment Outcome; Urinary Bladder Neoplasms; Vaccines, Subunit | 2016 |
[Study on platinum concentration in internal iliac venous blood after iliac artery cisplatin infusion for invasive bladder cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Female; Humans; Iliac Vein; Male; Methotrexate; Middle Aged; Platinum; Urinary Bladder Neoplasms; Vinblastine | 1999 |
64 other study(ies) available for platinum and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms | 2022 |
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Phenylurea Compounds; Platinum; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |
Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Azacitidine; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; GATA3 Transcription Factor; Humans; Male; Nuclear Proteins; Platinum; Prognosis; Pyridines; Urinary Bladder Neoplasms | 2022 |
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Platinum; Spironolactone; Urinary Bladder Neoplasms | 2022 |
Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.
Topics: Hemoglobins; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Nomograms; Platinum; Programmed Cell Death 1 Receptor; Steroids; Urinary Bladder Neoplasms | 2022 |
Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer.
Topics: B7-H1 Antigen; Epitopes; Female; Granzymes; Humans; Male; Platinum; Urinary Bladder Neoplasms | 2022 |
Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
Topics: Carcinoma, Transitional Cell; Humans; Hypoalbuminemia; Immune Checkpoint Inhibitors; Platinum; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
Topics: Aged; Combined Modality Therapy; Cystectomy; Fluorouracil; Humans; Muscles; Neoplasm Invasiveness; Organ Sparing Treatments; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Immunotherapy; Neoadjuvant Therapy; Platinum; Urinary Bladder Neoplasms | 2022 |
Comments on "Survival after neoadjuvant/induction combination immunotherapy versus combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Immunotherapy; Neoadjuvant Therapy; Platinum; Urinary Bladder Neoplasms | 2022 |
Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Transitional Cell; Humans; Nivolumab; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Transitional Cell; CD8-Positive T-Lymphocytes; Humans; Lymphocytes, Tumor-Infiltrating; Platinum; Prognosis; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein | 2022 |
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Methotrexate; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2023 |
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy.
Topics: Cell Line, Tumor; Glutathione; Humans; Nanoparticles; Oligopeptides; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Platinum; Polyethylene Glycols; Prodrugs; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Middle Aged; Platinum; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Medicare; Platinum; Retrospective Studies; United States; Urinary Bladder Neoplasms | 2023 |
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Topics: Carcinoma, Transitional Cell; Cost-Effectiveness Analysis; Humans; Platinum; Taiwan; Urinary Bladder Neoplasms | 2023 |
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Propensity Score; Urinary Bladder Neoplasms | 2023 |
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Hemoglobins; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Topics: Humans; Immune Checkpoint Inhibitors; Platinum; Procollagen-Proline Dioxygenase; Prognosis; Protein Disulfide-Isomerases; RNA, Small Interfering; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Propensity Score; Urinary Bladder Neoplasms | 2023 |
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Switzerland; Urinary Bladder Neoplasms | 2020 |
Platinum(II) ring-fused chlorins as efficient theranostic agents: Dyes for tumor-imaging and photodynamic therapy of cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Fluorescent Dyes; Humans; Melanoma; Molecular Structure; Optical Imaging; Photochemotherapy; Platinum; Porphyrins; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2020 |
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Receptor, Fibroblast Growth Factor, Type 3; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Topics: B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Platinum; Prognosis; Urinary Bladder Neoplasms; Urologic Neoplasms | 2021 |
Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur
Topics: Carcinoma, Transitional Cell; Cisplatin; Humans; Mutation; Platinum; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2021 |
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Platinum; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Topics: Aged; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Nivolumab; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Progression-Free Survival; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Inhibitory effect of Au@Pt-NSs on proliferation, migration, and invasion of EJ bladder carcinoma cells: involvement of cell cycle regulators, signaling pathways, and transcription factor-mediated MMP-9 expression.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Gold; Humans; Matrix Metalloproteinase 9; Nanostructures; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Platinum; Signal Transduction; Transcription Factors; Urinary Bladder Neoplasms | 2018 |
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in
Topics: Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Mutation; Nuclear Proteins; Platinum; Precision Medicine; Transcription Factors; Urinary Bladder Neoplasms | 2019 |
Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Recurrence; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2014 |
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Paclitaxel; Platinum; Signal Transduction; Transcription Factor RelA; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cation Transport Proteins; Copper Transporter 1; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Urinary Bladder Neoplasms | 2016 |
Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cisplatin; DNA; DNA Breaks; Drug Resistance, Neoplasm; Humans; Nitrogen Oxides; Platinum; Platinum Compounds; Urinary Bladder Neoplasms | 2017 |
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Anemia; Disease Progression; Europe; Female; Humans; Kidney Diseases; Liver Neoplasms; Male; Neoplasm Metastasis; Platinum; Practice Guidelines as Topic; Treatment Failure; Urinary Bladder Neoplasms; Urothelium | 2016 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Bladder cancer: Mutations in DNA-damage-repair pathways confer platinum sensitivity.
Topics: DNA; DNA Damage; Humans; Mutation; Platinum; Urinary Bladder Neoplasms | 2017 |
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; DNA Repair; Female; Genetic Variation; Humans; Male; Middle Aged; Platinum; Polymorphism, Genetic; Predictive Value of Tests; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
Pt(II) complexes with N-(3-pyridyl)-2-(4-(trifluoromethyl)phenyl)diazenecarboxamide and their reactions with glutathione.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Glutathione; Humans; Hydrocarbons, Chlorinated; Imides; Magnetic Resonance Spectroscopy; Molecular Structure; Organoplatinum Compounds; Oxidation-Reduction; Platinum; Pyridines; Sulfhydryl Compounds; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Hematoporphyrins; Humans; Ligands; Models, Chemical; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Photosensitizing Agents; Platinum; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2004 |
Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; DNA, Neoplasm; Drug Screening Assays, Antitumor; Hematoporphyrins; Humans; Organoplatinum Compounds; Photosensitizing Agents; Platinum; Porphyrins; Spheroids, Cellular; Tissue Distribution; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |
Platinum kinetics in patients treated with cis-dichlorodiammine platinum (II).
Topics: Aged; Cisplatin; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Neoplasm Metastasis; Platinum; Urinary Bladder Neoplasms | 1982 |
Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Invasiveness; Platinum; Rabbits; Urinary Bladder Neoplasms | 1997 |
Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines.
Topics: Carcinoma, Transitional Cell; Cisplatin; Drug Resistance, Neoplasm; Humans; Platinum; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Bladder carcinoma at University of Iowa Hospital and Clinics.
Topics: Antineoplastic Agents; Female; Hospitals, University; Humans; Male; Platinum; Tretinoin; Urinary Bladder Neoplasms | 1978 |
[Angiographic analysis of intratumoral Pt concentration on intra-arterial infusion therapy for bladder cancer].
Topics: Aged; Angiography; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Platinum; Regional Blood Flow; Urinary Bladder; Urinary Bladder Neoplasms | 1991 |
[CDDP concentration of bladder tumors--comparison between intraarterial infusion and intravenous infusion].
Topics: Aged; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Platinum; Urinary Bladder Neoplasms | 1988 |
[Platinum concentrations in human tissue after administration of cisplatin].
Topics: Adolescent; Adult; Aged; Child, Preschool; Cisplatin; Female; Humans; Male; Middle Aged; Platinum; Spectrophotometry, Atomic; Testicular Neoplasms; Tissue Distribution; Urinary Bladder Neoplasms | 1988 |
Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
Topics: Cell Line; Cell Survival; Cisplatin; DNA Repair; DNA Replication; DNA, Neoplasm; Humans; Kinetics; Male; Platinum; Radioisotopes; Testicular Neoplasms; Urinary Bladder Neoplasms | 1988 |
Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor.
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Carcinoma, Transitional Cell; Cisplatin; Female; Infusions, Intra-Arterial; Kidney; Neoplasm Transplantation; Platinum; Rats; Rats, Inbred Strains; Thiosulfates; Tissue Distribution; Urinary Bladder Neoplasms | 1987 |
Effect of chemotherapeutic agents on bladder cancer: a new animal model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamines; Disease Models, Animal; Doxorubicin; Fluorouracil; Hydroxyurea; Lomustine; Mice; Mice, Inbred C3H; Platinum; Urinary Bladder Neoplasms | 1973 |